Printer Friendly

New treatment shuts off oncogene.

A gene known as p53 plays a role in the development of many cancers, including a severe type of leukemia -- cancer of blood and bone marrow cells. This gene is turned off in most immature bone marrow cells. However, scientists believe that cancer arises when something turns p53 on at an inappropriate time, causing blood and bone marrow cells to proliferate.

On the basis of this hypothesis, Jorge Spinolo of the University of Nebraska Medical Center in Omaha and his colleagues devised a treatment strategy, using so-called anti-sense molecules (SN: 6/10/89, p.360), for acute myelogenous leukemia (AML). The technique blocks the activity of the p53 gene. In laboratory studies, the new treatment has slowed the growth of malignant cells obtained from people suffering from AML. That in vitro finding raises the hope that a similar strategy might help combat leukemic cells in the human body, not just in a petri dish.

Before Spinolo's group could test the treatment's efficacy, the researchers had to demonstrate its safety. They gave the new drug to seven monkeys. Several weeks later, the team sacrificed four of the monkeys and found no evidence of drug-related toxicity.

The remaining three monkeys are alive and well, Spinolo reported May 22 at the American Association for Cancer Research meeting in San Diego.

Spinolo wants to treat 10 to 15 AML patients with the drug and plans to take such a research proposal to the U.S. Food and Drug Administration this month. If the team gains FDA approval, that preliminary human trial would begin sometime this summer, Spinolo says.
COPYRIGHT 1992 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:using anti-sense molecules to treat leukemia
Publication:Science News
Article Type:Brief Article
Date:Jun 6, 1992
Previous Article:Glow little stressed plant, glow.
Next Article:Not all semen infected alike.

Related Articles
Backward genetics: knocking some 'antisense' into wayward genes.
Upping the antisense ante: scientists bet on profits from reverse genetics.
Blood-vessel growth genes stop making sense.
'Anti-gene' therapy shows promise....
...When melded with gene transfer.
Making sense of antisense in cancer.
Reverse logic: smart drugs target HIV and a herpesvirus.
Findings on Anticancer Compound That Acts Against Telomerase To Be Published in Leading Journal, Oncogene.
Biotechnology and drug discovery: from bench to bedside.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters